Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05969691Not ApplicableActive Not Recruiting

Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas

Role: lead

NCT05656053Active Not Recruiting

Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging

Role: lead

NCT05739500Unknown

MRI-based Computer Aided Diagnosis Software (V1) for Glioma

Role: lead

All 3 trials loaded